These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 18841517)

  • 1. Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: a case study with melanocortin-4 receptor agonists.
    Tang W; Stearns RA; Wang RW; Miller RR; Chen Q; Ngui J; Bakshi RK; Nargund RP; Dean DC; Baillie TA
    Xenobiotica; 2008 Nov; 38(11):1437-51. PubMed ID: 18841517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4.
    Sahali-Sahly Y; Balani SK; Lin JH; Baillie TA
    Chem Res Toxicol; 1996 Sep; 9(6):1007-12. PubMed ID: 8870989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of the enzyme(s) involved in the metabolism of amiodarone in liver and intestine of rat: the contribution of cytochrome P450 3A isoforms.
    Shayeganpour A; El-Kadi AO; Brocks DR
    Drug Metab Dispos; 2006 Jan; 34(1):43-50. PubMed ID: 16204463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2C8- and CYP3A-mediated C-demethylation of (3-{[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance.
    Prakash C; Wang W; O'Connell T; Johnson KA
    Drug Metab Dispos; 2008 Oct; 36(10):2093-103. PubMed ID: 18653741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioactivation of isothiazoles: minimizing the risk of potential toxicity in drug discovery.
    Teffera Y; Choquette D; Liu J; Colletti AE; Hollis LS; Lin MH; Zhao Z
    Chem Res Toxicol; 2010 Nov; 23(11):1743-52. PubMed ID: 20825217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
    Lu C; Balani SK; Qian MG; Prakash SR; Ducray PS; von Moltke LL
    J Pharmacol Exp Ther; 2010 Feb; 332(2):562-8. PubMed ID: 19889796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine.
    Zhao SX; Dalvie DK; Kelly JM; Soglia JR; Frederick KS; Smith EB; Obach RS; Kalgutkar AS
    Chem Res Toxicol; 2007 Nov; 20(11):1649-57. PubMed ID: 17907785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors.
    Li P; Lu C; Balani SK; Gan LS
    Drug Metab Dispos; 2011 Jun; 39(6):1054-7. PubMed ID: 21393461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design.
    Perloff ES; Mason AK; Dehal SS; Blanchard AP; Morgan L; Ho T; Dandeneau A; Crocker RM; Chandler CM; Boily N; Crespi CL; Stresser DM
    Xenobiotica; 2009 Feb; 39(2):99-112. PubMed ID: 19255936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
    Obach RS; Walsky RL; Venkatakrishnan K; Gaman EA; Houston JB; Tremaine LM
    J Pharmacol Exp Ther; 2006 Jan; 316(1):336-48. PubMed ID: 16192315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of metabolites and cytochrome P450 isoforms involved in the microsomal metabolism of aconitine.
    Wang Y; Wang S; Liu Y; Yan L; Dou G; Gao Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Dec; 844(2):292-300. PubMed ID: 16949890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel bioactivation pathway for 2-[2-(2,6-dichlorophenyl)aminophenyl]ethanoic acid (diclofenac) initiated by cytochrome P450-mediated oxidative decarboxylation.
    Grillo MP; Ma J; Teffera Y; Waldon DJ
    Drug Metab Dispos; 2008 Sep; 36(9):1740-4. PubMed ID: 18541695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of drug-drug interaction via mechanism-based inhibition of cytochrome P450 3A by macrolides in dexamethasone-treated female rats.
    Kanazu T; Sato N; Kadono K; Touchi A; Takeda Y; Yamaguchi Y; Baba T
    Biopharm Drug Dispos; 2012 May; 33(4):195-206. PubMed ID: 22447511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A.
    Zhao P; Lee CA; Kunze KL
    Drug Metab Dispos; 2007 May; 35(5):704-12. PubMed ID: 17293381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats.
    Chen Q; Doss GA; Tung EC; Liu W; Tang YS; Braun MP; Didolkar V; Strauss JR; Wang RW; Stearns RA; Evans DC; Baillie TA; Tang W
    Drug Metab Dispos; 2006 Jan; 34(1):145-51. PubMed ID: 16251255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation.
    Chen Q; Ngui JS; Doss GA; Wang RW; Cai X; DiNinno FP; Blizzard TA; Hammond ML; Stearns RA; Evans DC; Baillie TA; Tang W
    Chem Res Toxicol; 2002 Jul; 15(7):907-14. PubMed ID: 12119000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of imidazole- and 2-methyl imidazole-containing farnesyl-protein transferase inhibitors: interaction with and metabolism by rat hepatic cytochrome P450s.
    Tang C; Chiba M; Nishime J; Hochman JH; Chen I; Williams TM; Lin JH
    Drug Metab Dispos; 2000 Jun; 28(6):680-6. PubMed ID: 10820141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of DHEA by cytochromes P450 in rat and human liver microsomal fractions.
    Fitzpatrick JL; Ripp SL; Smith NB; Pierce WM; Prough RA
    Arch Biochem Biophys; 2001 May; 389(2):278-87. PubMed ID: 11339818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic activation of a novel 3-substituted indole-containing TNF-alpha inhibitor: dehydrogenation and inactivation of CYP3A4.
    Sun H; Yost GS
    Chem Res Toxicol; 2008 Feb; 21(2):374-85. PubMed ID: 18095656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen.
    O'Donnell JP; Dalvie DK; Kalgutkar AS; Obach RS
    Drug Metab Dispos; 2003 Nov; 31(11):1369-77. PubMed ID: 14570769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.